gilotrifhcp.com Report : Visit Site


  • Ranking Alexa Global: # 15,429,810

    Server:Apache/2.2.15...

    The main IP address: 77.246.39.195,Your server United Kingdom,London ISP:Datapipe  TLD:com CountryCode:GB

    The description :learn more about gilotrif (afatinib) tablets, a treatment for patients with del 19 or l858r egfr mutation-positive mnsclc, or patients with metastatic squamous nsclc progressing after platinum-based c...

    This report updates in 01-Aug-2018

Created Date:2016-07-13
Changed Date:2018-07-12

Technical data of the gilotrifhcp.com


Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host gilotrifhcp.com. Currently, hosted in United Kingdom and its service provider is Datapipe .

Latitude: 51.508529663086
Longitude: -0.12574000656605
Country: United Kingdom (GB)
City: London
Region: England
ISP: Datapipe
    woodcraft-uk.com 

HTTP Header Analysis


HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.2.15 containing the details of what the browser wants and will accept back from the web server.

X-Drupal-Cache:HIT
Content-Language:en
Content-Encoding:gzip
Transfer-Encoding:chunked
Expires:Sun, 19 Nov 1978 05:00:00 GMT
Vary:Cookie,User-Agent,Accept-Encoding
Keep-Alive:timeout=4, max=500
Server:Apache/2.2.15
Last-Modified:Wed, 01 Aug 2018 12:47:17 GMT
Connection:Keep-Alive
Etag:"1533127637-1"
Link:; rel="canonical",; rel="shortlink"
X-UA-Compatible:IE=edge,chrome=IE8
Cache-Control:private
Date:Wed, 01 Aug 2018 13:21:32 GMT
X-Frame-Options:SAMEORIGIN
Content-Type:text/html; charset=utf-8
X-Generator:Drupal 7 (http://drupal.org)

DNS

soa:obs.ns1.fr. technical.nameshield.net. 2018061204 28800 7200 604800 7200
txt:"v5kmfly87l6y2523lqxxfn7yzr26wjjc"
"v=spf1 include:_spf.boehringer-ingelheim.com -all"
ns:ns3.nameshield.net.
obs.ns1.fr.
ns2.observatoiredesmarques.fr.
ipv4:IP:77.246.39.195
ASN:24778
OWNER:DATAPIPE-UK, GB
Country:GB
mx:MX preference = 10, mail exchanger = mail3.boehringer-ingelheim.com.
MX preference = 10, mail exchanger = mail2.boehringer-ingelheim.com.
MX preference = 10, mail exchanger = mail1.boehringer-ingelheim.com.
MX preference = 10, mail exchanger = mail4.boehringer-ingelheim.com.

HtmlToText

") //-- ") //-- patients & caregivers solutions plus® menu indications and usage important safety information prescribing information gilotrif patient services gilotrif patient services start your patients on gilotrif > for patients patients & caregivers healthcare professionals gilotrif® patient services 10 reasons to prescribe gilotrif gilotrif: well established, well studied in over 4200 patients dosing and administration patient and provider resources resources for your patients resources for you access support online resources for non-dispensing accounts prescribing gilotrif access & support gilotrif dose exchange™ patient roadmap for dispensing pharmacies access & support gilotrif dose exchange ™ patient & caregiver resources patient roadmap enrollment forms gilotrif® patient services *not an actual patient. develop a comprehensive treatment plan with your egfr m+ mnsclc patients meet sarah* *not an actual patient. egfr m+=epidermal growth factor receptor mutation positive; mnsclc=metastatic non-small cell lung cancer. scroll to read about her treatment plan. gilotrif achieved nearly 3 years overall survival (os) in patients with del19 mutations 1,2 † sarah is diagnosed with egfr m+ mnsclc with a del19 mutation and started gilotrif as first‑line treatment. median os in lux-lung 3 : del19 mutations population 1,2 view safety information from lux-lung 3. median pfs: 13.7 months with afatinib vs 5.6 months with pemetrexed-cisplatin (hr: 0.28; 95% ci, 0.18–0.44) 1,3,4 ci=confidence interval; hr=hazard ratio. sarah is diagnosed with egfr m+ mnsclc with a del19 mutation and started gilotrif as first‑line treatment back to top the majority of patients, like sarah, go on to develop a t790m mutation after treatment with first- or second‑generation egfr tkis 5 tki=tyrosine kinase inhibitor. back to top tki=tyrosine kinase inhibitor. know your patients' options. start with first-line gilotrif. proven efficacy in even more egfr mutations 1 only oral agent approved in sqcc of the lung 1,6 start your patients on gilotrif sqcc=squamous cell carcinoma. back to top important safety information and indications and usage for gilotrif® (afatinib) tablets warnings and precautions important safety information for gilotrif® (afatinib) tablets warnings and precautions diarrhea gilotrif can cause diarrhea which may be severe and can result in dehydration with or without renal impairment. in clinical studies, some of these cases were fatal. for patients who develop grade 2 diarrhea lasting more than 48 hours or grade 3 or greater diarrhea, withhold gilotrif until diarrhea resolves to grade 1 or less, and then resume at a reduced dose. provide patients with an anti‑diarrheal agent (e.g., loperamide) for self‑administration at the onset of diarrhea and instruct patients to continue anti‑diarrheal until loose stools cease for 12 hours. bullous and exfoliative skin disorders gilotrif can result in cutaneous reactions consisting of rash, erythema, and acneiform rash. in addition, palmar-plantar erythrodysesthesia syndrome was observed in clinical trials in patients taking gilotrif. discontinue gilotrif in patients who develop life-threatening bullous, blistering, or exfoliating lesions. for patients who develop grade 2 cutaneous adverse reactions lasting more than 7 days, intolerable grade 2, or grade 3 cutaneous reactions, withhold gilotrif. when the adverse reaction resolves to grade 1 or less, resume gilotrif with appropriate dose reduction. postmarketing cases of toxic epidermal necrolysis (ten) and stevens johnson syndrome (sjs) have been reported in patients receiving gilotrif. discontinue gilotrif if ten or sjs is suspected. interstitial lung disease interstitial lung disease (ild) or ild-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in patients receiving gilotrif in clinical trials. in some cases, ild was fatal. the incidence of ild appeared to be higher in asian patients as compared to white patients. withhold gilotrif during evaluation of patients with suspected ild, and discontinue gilotrif in patients with confirmed ild. hepatic toxicity hepatic toxicity as evidenced by liver function tests abnormalities has been observed in patients taking gilotrif. in 4257 patients who received gilotrif across clinical trials, 9.7% had liver test abnormalities, of which 0.2% were fatal. obtain periodic liver testing in patients during treatment with gilotrif. withhold gilotrif in patients who develop worsening of liver function. treatment should be discontinued in patients who develop severe hepatic impairment while taking gilotrif. keratitis keratitis has been reported in patients taking gilotrif. withhold gilotrif during evaluation of patients with suspected keratitis. if diagnosis of ulcerative keratitis is confirmed, treatment with gilotrif should be interrupted or discontinued. if keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered. gilotrif should be used with caution in patients with a history of keratitis, ulcerative keratitis, or severe dry eye. contact lens use is also a risk factor for keratitis and ulceration. embryo-fetal toxicity gilotrif can cause fetal harm when administered to a pregnant woman. advise pregnant women and females of reproductive potential of the potential risk to a fetus. advise females of reproductive potential to use effective contraception during treatment, and for at least 2 weeks after the last dose of gilotrif. advise female patients to contact their healthcare provider with a known or suspected pregnancy. adverse reactions adverse reactions observed in clinical trials were as follows: first-line treatment of egfr mutation-positive, metastatic nsclc in gilotrif-treated patients (n=229) the most common adverse reactions (≥20% all grades & vs pemetrexed/cisplatin-treated patients (n=111)) were diarrhea (96% vs 23%), rash/acneiform dermatitis (90% vs 11%), stomatitis (71% vs 15%), paronychia (58% vs 0%), dry skin (31% vs 2%) and pruritus (21% vs 1%). other clinically important adverse reactions observed in patients treated with gilotrif include: decreased appetite (29%), nausea (25%), and vomiting (23%). serious adverse reactions were reported in 29% of patients treated with gilotrif. the most frequent serious adverse reactions reported in patients treated with gilotrif were diarrhea (6.6%), vomiting (4.8%), and dyspnea, fatigue, and hypokalemia (1.7% each). fatal adverse reactions in gilotrif-treated patients included pulmonary toxicity/ild-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%). more gilotrif-treated patients (2.2%) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all < grade 3) compared to chemotherapy‑treated patients (0.9%). previously treated metastatic squamous nsclc in gilotrif-treated patients (n=392) the most common adverse reactions (≥20% all grades & vs erlotinib-treated patients (n=395)) were diarrhea (75% vs 41%), rash/acneiform dermatitis (70% vs 70%), stomatitis (30% vs 11%), decreased appetite (25% vs 26%), nausea (21% vs 16%). serious adverse reactions were reported in 44% of patients treated with gilotrif. the most frequent serious adverse reactions reported in patients treated with gilotrif were pneumonia (6.6%), diarrhea (4.6%), and dehydration and dyspnea (3.1% each). fatal adverse reactions in gilotrif-treated patients included ild (0.5%), pneumonia (0.3%), respiratory failure (0.3%), acute renal failure (0.3%), and general physical health deterioration (0.3%). drug interactions effect of p‑glycoprotein (p‑gp) inhibitors and inducers concomitant use of p-gp inhibitors (including but not limited to ritonavir, cyclosporine a, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with gilo

URL analysis for gilotrifhcp.com


https://www.gilotrifhcp.com/efficacy-safety#reason6
https://www.gilotrifhcp.com/clinical-practice-patient-resources#resources-for-you
https://www.gilotrifhcp.com/efficacy-safety
https://www.gilotrifhcp.com/efficacy-safety#reason3
https://www.gilotrifhcp.com/clinical-practice-patient-resources#access-support
https://www.gilotrifhcp.com/solutions-plus
https://www.gilotrifhcp.com/efficacy-safety#reason11
https://www.gilotrifhcp.com/efficacy-safety#reason12
https://www.gilotrifhcp.com/sitemap
https://www.gilotrifhcp.com/#section04
https://www.gilotrifhcp.com/#section03
https://www.gilotrifhcp.com/#section02
https://www.gilotrifhcp.com/clinical-practice-patient-resources#online-resources
https://www.gilotrifhcp.com/clinical-practice-patient-resources
https://www.gilotrifhcp.com/clinical-practice-patient-resources#resources-for-your-patients

Whois Information


Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: GILOTRIFHCP.COM
Registry Domain ID: 2042463863_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corehub.net
Registrar URL: http://corehub.net
Updated Date: 2018-07-12T07:09:24Z
Creation Date: 2016-07-13T07:22:34Z
Registry Expiry Date: 2020-07-13T07:22:34Z
Registrar: Corehub, S.R.L.
Registrar IANA ID: 15
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +34935275235
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS2.OBSERVATOIREDESMARQUES.FR
Name Server: NS3.NAMESHIELD.NET
Name Server: OBS.NS1.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-08-01T13:21:18Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Corehub, S.R.L.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =gilotrifhcp.com

  PORT 43

  TYPE domain

DOMAIN

  NAME gilotrifhcp.com

  CHANGED 2018-07-12

  CREATED 2016-07-13

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS2.OBSERVATOIREDESMARQUES.FR 80.74.69.8

  NS3.NAMESHIELD.NET 45.63.17.113

  OBS.NS1.FR 81.92.84.146

  REGISTERED yes

Go to top

Mistakes


The following list shows you to spelling mistakes possible of the internet users for the website searched .

  • www.ugilotrifhcp.com
  • www.7gilotrifhcp.com
  • www.hgilotrifhcp.com
  • www.kgilotrifhcp.com
  • www.jgilotrifhcp.com
  • www.igilotrifhcp.com
  • www.8gilotrifhcp.com
  • www.ygilotrifhcp.com
  • www.gilotrifhcpebc.com
  • www.gilotrifhcpebc.com
  • www.gilotrifhcp3bc.com
  • www.gilotrifhcpwbc.com
  • www.gilotrifhcpsbc.com
  • www.gilotrifhcp#bc.com
  • www.gilotrifhcpdbc.com
  • www.gilotrifhcpfbc.com
  • www.gilotrifhcp&bc.com
  • www.gilotrifhcprbc.com
  • www.urlw4ebc.com
  • www.gilotrifhcp4bc.com
  • www.gilotrifhcpc.com
  • www.gilotrifhcpbc.com
  • www.gilotrifhcpvc.com
  • www.gilotrifhcpvbc.com
  • www.gilotrifhcpvc.com
  • www.gilotrifhcp c.com
  • www.gilotrifhcp bc.com
  • www.gilotrifhcp c.com
  • www.gilotrifhcpgc.com
  • www.gilotrifhcpgbc.com
  • www.gilotrifhcpgc.com
  • www.gilotrifhcpjc.com
  • www.gilotrifhcpjbc.com
  • www.gilotrifhcpjc.com
  • www.gilotrifhcpnc.com
  • www.gilotrifhcpnbc.com
  • www.gilotrifhcpnc.com
  • www.gilotrifhcphc.com
  • www.gilotrifhcphbc.com
  • www.gilotrifhcphc.com
  • www.gilotrifhcp.com
  • www.gilotrifhcpc.com
  • www.gilotrifhcpx.com
  • www.gilotrifhcpxc.com
  • www.gilotrifhcpx.com
  • www.gilotrifhcpf.com
  • www.gilotrifhcpfc.com
  • www.gilotrifhcpf.com
  • www.gilotrifhcpv.com
  • www.gilotrifhcpvc.com
  • www.gilotrifhcpv.com
  • www.gilotrifhcpd.com
  • www.gilotrifhcpdc.com
  • www.gilotrifhcpd.com
  • www.gilotrifhcpcb.com
  • www.gilotrifhcpcom
  • www.gilotrifhcp..com
  • www.gilotrifhcp/com
  • www.gilotrifhcp/.com
  • www.gilotrifhcp./com
  • www.gilotrifhcpncom
  • www.gilotrifhcpn.com
  • www.gilotrifhcp.ncom
  • www.gilotrifhcp;com
  • www.gilotrifhcp;.com
  • www.gilotrifhcp.;com
  • www.gilotrifhcplcom
  • www.gilotrifhcpl.com
  • www.gilotrifhcp.lcom
  • www.gilotrifhcp com
  • www.gilotrifhcp .com
  • www.gilotrifhcp. com
  • www.gilotrifhcp,com
  • www.gilotrifhcp,.com
  • www.gilotrifhcp.,com
  • www.gilotrifhcpmcom
  • www.gilotrifhcpm.com
  • www.gilotrifhcp.mcom
  • www.gilotrifhcp.ccom
  • www.gilotrifhcp.om
  • www.gilotrifhcp.ccom
  • www.gilotrifhcp.xom
  • www.gilotrifhcp.xcom
  • www.gilotrifhcp.cxom
  • www.gilotrifhcp.fom
  • www.gilotrifhcp.fcom
  • www.gilotrifhcp.cfom
  • www.gilotrifhcp.vom
  • www.gilotrifhcp.vcom
  • www.gilotrifhcp.cvom
  • www.gilotrifhcp.dom
  • www.gilotrifhcp.dcom
  • www.gilotrifhcp.cdom
  • www.gilotrifhcpc.om
  • www.gilotrifhcp.cm
  • www.gilotrifhcp.coom
  • www.gilotrifhcp.cpm
  • www.gilotrifhcp.cpom
  • www.gilotrifhcp.copm
  • www.gilotrifhcp.cim
  • www.gilotrifhcp.ciom
  • www.gilotrifhcp.coim
  • www.gilotrifhcp.ckm
  • www.gilotrifhcp.ckom
  • www.gilotrifhcp.cokm
  • www.gilotrifhcp.clm
  • www.gilotrifhcp.clom
  • www.gilotrifhcp.colm
  • www.gilotrifhcp.c0m
  • www.gilotrifhcp.c0om
  • www.gilotrifhcp.co0m
  • www.gilotrifhcp.c:m
  • www.gilotrifhcp.c:om
  • www.gilotrifhcp.co:m
  • www.gilotrifhcp.c9m
  • www.gilotrifhcp.c9om
  • www.gilotrifhcp.co9m
  • www.gilotrifhcp.ocm
  • www.gilotrifhcp.co
  • gilotrifhcp.comm
  • www.gilotrifhcp.con
  • www.gilotrifhcp.conm
  • gilotrifhcp.comn
  • www.gilotrifhcp.col
  • www.gilotrifhcp.colm
  • gilotrifhcp.coml
  • www.gilotrifhcp.co
  • www.gilotrifhcp.co m
  • gilotrifhcp.com
  • www.gilotrifhcp.cok
  • www.gilotrifhcp.cokm
  • gilotrifhcp.comk
  • www.gilotrifhcp.co,
  • www.gilotrifhcp.co,m
  • gilotrifhcp.com,
  • www.gilotrifhcp.coj
  • www.gilotrifhcp.cojm
  • gilotrifhcp.comj
  • www.gilotrifhcp.cmo
Show All Mistakes Hide All Mistakes